About Scilex Holding
Scilex Holding is a company based in Palo Alto (United States) founded in 2019. The company has 115 employees as of December 31, 2024. Scilex Holding has completed 1 acquisition, including Ancora Medical. Scilex Holding offers products and services including ZTLido, Elyxyb, and Gloperba. Scilex Holding operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Palo Alto, United States
- Employees 115 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scilex Holding Company
-
Annual Revenue
$56.59 M (USD)21.07as on Dec 31, 2024
-
Net Profit
-$72.81 M (USD)36.32as on Dec 31, 2024
-
EBITDA
-$88.74 M (USD)12.38as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
115
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scilex Holding
Scilex Holding is a publicly listed company on the NASDAQ with ticker symbol SCLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scilex Holding
Scilex Holding offers a comprehensive portfolio of products and services, including ZTLido, Elyxyb, and Gloperba.
Optimizes drug delivery for chronic pain through proprietary adhesion.
Provides fast relief for migraines with individualized dosing options.
Offers precision dosing as the first liquid gout medicine available.
Funding Insights of Scilex Holding
Detailed funding history for Scilex Holding
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scilex Holding
Scilex Holding has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ancora Medical.
Investment portfolio details for Scilex Holding
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of a surgical pain management device
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Scilex Holding
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Scilex Holding
Detailed financials for Scilex Holding
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scilex Holding Comparisons
Peer comparison for Scilex Holding
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scilex Holding
Scilex Holding operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
Detailed competitors of Scilex Holding
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scilex Holding
Complete news archive for Scilex Holding
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scilex Holding
Scilex Holding was founded in 2019.
Scilex Holding is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Jaisim Shah is the current CEO of Scilex Holding.
As of Dec 31, 2024, the latest employee count at Scilex Holding is 115.
Annual revenue of Scilex Holding is $56.59M as on Dec 31, 2024.
Developer of non-opioid therapies for acute and chronic pain. It offers a lead product Tlido a lidocaine topical product for post-shingles nerve pain. It also has other candidates SP-102 to treat lumbosacral radicular pain, SP-103 for the treatment of low back pain, and SP-104 for chronic pain and fibromyalgia.
Scilex Holding's top competitors include Flexion Therapeutics, scPharmaceuticals and Cara Therapeutics.
Scilex Holding offers ZTLido, Elyxyb, and Gloperba.
Yes, Scilex Holding is publicly traded on NASDAQ under the ticker symbol SCLX.
Scilex Holding has made 1 acquisition, including Ancora Medical.
The ticker symbol of Scilex Holding is SCLX on NASDAQ.